Data as of Mar 11
| -0.31 / -0.95%|
CSL Ltd. is engaged in the manufacturing and distributing of biopharmaceutical and allied products. The company's areas of expertise include plasma products, vaccines and pharmaceuticals and research and development. It operates through the following segments: CSL Behring, bioCSL and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies, which includes plasma products and recombinants. The bioCSL segment manufactures and distributes non-plasma biotherapeutic products. The CSL Intellectual Property segment licenses intellectual property to unrelated third parties. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.
|Paul Roger Perreault||Chief Executive Officer, Executive Director & MD|
|Gordon Naylor||Chief Financial Officer|
|Andrew Cuthbertson||Chief Scientific Officer|
|Mark Dehring||Director-Investor Relations|
|Sharon McHale||Senior Director-Public Affairs|